On the morning of January 18, the third plenary session of the 14th National People's Congress of Hunan Province was held to elect 118 delegates of Hunan Province to the 14th National People's Congress, and Dai Lizhong, President of Sansure Bio, was elected.

On January 18, Shanghai Kehua Bio-Engineering Co., Ltd. released the 2022 annual fiscal forecast.

ALiA BioTech group has announced the deployment of its Lab-on-Chip diagnostic platform, which can perform multiplex testing using a single biochip.

Cytovale® announced today that its IntelliSep® test has received U.S. Food and Drug Administration 510(k) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments each year.

On January 17, Top Employers Institute, a global employer research organization, officially announced the 2023 ¡°Top Employer China¡± list. A number of IVD-related enterprises have passed the rigorous evaluation of 20 subjects in six areas of human resources and won the ¡°Top Employer China 2023¡±.

PAVmed Inc., a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a strategic business update, outlining near-term strategic priorities and resource reallocation.

QIAGEN today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after being made available for research.

GE HealthCare, a leader in precision care innovation, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022. The Company also issued Organic revenue growth, Adjusted EBIT margin, and Free cash flow conversion guidance for 2023.

THERADIAG, a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics, today reported its 2022 annual revenue and its cash position at December 31, 2022.

New Horizon Health announced earnings forecast for financial year 2022: total revenue expected to be RMB 766 million, up 260% year-on-year; Bioeasy 2022 expected net profit CNY 110 million to CNY 150 million

On January 14, Shenzhen YHLO Biotech Co., Ltd. released the 2022 annual performance forecast.

Healthcare and life science firms Pierian, Seven Bridges, and UgenTec have been acquired by investment fund Summa Equity for an undisclosed amount and merged to form a new precision medicine company, Velsera.

The US Food and Drug Administration recently granted Emergency Use Authorization for Scope Molecular Laboratory's SARS nCoV-2019 Multiplexed Assay for serial COVID-19 testing.

Agilent Technologies Inc. (NYSE: A) today announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company¡¯s high-quality active pharmaceutical ingredients (API).

Bioantibody has completed its first round of financing totaling nearly 100 million yuan. This financing was led by Fang Fund and followed by New Industry Investment, Guoqian Venture Investment, Bondshine Capital. Phoenix Tree Capital acted as the exclusive financial advisor.